Directorate Update
Updated : 13:25
25 June 2019
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Directorate Update
The Board has made excellent progress in selecting a further independent non-executive director. An appointment is expected by the end of August 2019. Following further consideration of the Board composition, the Board has concluded that Brendan Buckley will no longer be considered an "independent director" with respect to the Company's application of the QCA Code. The Board reiterates its view that Brendan Buckley is of independent character and judgement and will play a key role in the development of Venn Life Sciences from his position as Chairman. Additionally, reference to "UK Corporate Governance Code" on page 23 of the Admission Document refers to the QCA Code.
The Board is committed to upholding the highest standards of corporate governance. Further detail of the Board's approach to corporate governance is available on the Company's website at www. vennlifesciences.com/investors/.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 5499 341
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn Life Sciences has dedicated operations in France, Germany, the Netherlands, the UK and Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.Vennlifesciences.com
Venn Life Sciences: getintouch@Vennlife.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.